c/retatrutide · created 6 Sep 2023
Triple agonist. Phase 3 data, research-grade material, and a lot of unknowns.
Jastreboff et al., N Engl J Med , 2023. Phase 2. Forty-eight weeks. Mean change −24.2% in the highest dose arm. Every one of those qualifiers gets dropped when the…
two reta batches, two services, 98.4% and 97.9%, and before anyone asks: same batch throughout, single submission, no cherry-picking between services. 98.4% and 97.9%.…
went too fast on reta and my resting HR told me before i noticed. Change my mind, genuinely — I have no stake in being right about this. Read the phase 2 paper twice…
the glucagon arm is why the appetite effect feels different — a position I have arrived at slowly and would like tested. Watched heart rate on a wearable across twelve…
Reference standards, analytical reagents and system-suitability material. If you are running your own method, start with a known.
Reference standardsPosting this as a discussion rather than a claim: this is not approved anywhere and half this community forgets that. What the glucagon arm is doing, as best anyone can…
reta phase 2 was -24.2% at 48 weeks and people quote it like it is a maintenance number. That is the headline. The document, the batch and the service are below so you…
Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.
Certified reference materials for peptide identity and purity work.
sigmaaldrich.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference